6 assets in Endometrial Undifferentiated Carcinoma

Therapeutic assets addressing Endometrial Undifferentiated Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Endometrial Undifferentiated Carcinoma	National Cancer Institute (NCI)	P2	B (59)
Capivasertib Endometrial Undifferentiated Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Durvalumab Endometrial Undifferentiated Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrial Undifferentiated Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Endometrial Undifferentiated Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Endometrial Undifferentiated Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)